Peri-operative radiotherapy for pancreatic ductal adenocarcinoma: current evidence and future directions: a narrative review

Perioperative RT may benefit selected PDAC patients when applied within a risk-adapted framework that accounts for underlying systemic-risk biology. Ongoing work is needed to determine which clinical or biologic markers reliably identify patients most likely to benefit from RT in the setting of intensified systemic therapy.